Tobias Agervald, Guard Therapeutics CEO
Swedish biotech Guard Therapeutics to stop PhII after interim review
Stockholm-based biotech Guard Therapeutics is stopping a Phase II trial of a protein drug that is meant to protect against acute kidney injury.
The biotech …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
